Volume 6.24 | Jun 23

Hematopoiesis News 6.24 June 23, 2015
Hematopoiesis News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   HN on Twitter
Scientists Identify Progenitor Cells for Blood and Immune System
Scientists showed that multipotent progenitor (MPP)2 and MPP3 are distinct myeloid-biased MPP subsets that work together with lymphoid-primed MPP4 cells to control blood production. They found that all MPPs are produced in parallel by hematopoietic stem cells, but with different kinetics and at variable levels depending on hematopoietic demands. [Cell Stem Cell] Press Release | Abstract | Graphical Abstract
Going to ISSCR 2015? We’ll see you there!
PUBLICATIONS (Ranked by impact factor of the journal)
The MicroRNA-132 and MicroRNA-212 Cluster Regulates Hematopoietic Stem Cell Maintenance and Survival with Age by Buffering FOXO3 Expression
Researchers found that the microRNA-212/132 cluster is enriched in hematopoietic stem cells and is upregulated during aging. Both overexpression and deletion of microRNAs in this cluster leads to inappropriate hematopoiesis with age. [Immunity] Abstract

Wnts Are Dispensable for Differentiation and Self-Renewal of Adult Murine Hematopoietic Stem Cells
The role of Wnts and their source in adult hematopoiesis is still unclear, and is clinically important as upstream Wnt inhibitors enter clinical trials. Scientists blocked Wnt secretion in hematopoietic lineages by targeting Porcn, a membrane-bound O-acyltransferase that is indispensable for the activity and secretion of all vertebrate Wnts. [Blood] Abstract

Control of AC133/CD133 and Impact on Human Hematopoietic Progenitor Cells through Nucleolin
Researchers dissected nucleolin-mediated activation of surface AC133 and its cognate gene CD133, via specific interaction of nucleolin with tissue-dependent CD133 promoter P1, as a mechanism that crucially contributes to AC133 expression in CD34+ hematopoietic stem/progenitor cell. [Leukemia] Abstract

Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death
Through a high-throughput cell-based screen, scientists identified avocatin B, a lipid derived from avocado fruit, as a novel compound with cytotoxic activity in acute myeloid leukemia (AML). Avocatin B reduced human primary AML cell viability without effect on normal peripheral blood stem cells. [Cancer Res]
| Press Release

Distinct Sources of Hematopoietic Progenitors Emerge before HSCs and Provide Functional Blood Cells in the Mammalian Embryo
The authors showed that the first murine definitive erythro-myeloid progenitors have an immunophenotype distinct from primitive hematopoietic progenitors, maturing megakaryocytes and macrophages, and rare B cell potential. [Cell Rep] Full Article | Graphical Abstract

Single-Stranded DNA-Binding Transcriptional Regulator FUBP1 Is Essential for Fetal and Adult Hematopoietic Stem Cell Self-Renewal
Scientists report the single-stranded DNA-binding transcriptional regulator far upstream element-binding protein 1 (FUBP1) as an essential factor of hematopoietic stem cell (HSC) self-renewal. Functional inactivation of FUBP1 in two different mouse models resulted in embryonic lethal anemia at around E15.5 caused by severely diminished HSCs. [Modern Pathol] Full Article | Graphical Abstract | Press Release

The Lysophosphatidic Acid Receptor LPA4 Regulates Hematopoiesis-Supporting Activity of Bone Marrow Stromal Cells
Researchers showed a novel regulatory role for lysophosphatidic acid (LPA)4 in hematopoiesis. Lpar4mRNA was predominantly expressed in mouse bone marrow PDGFRα+ stromal cells, known as the components of the hematopoietic stem/progenitor cell niche. [Sci Rep] Full Article


Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation for Adult Patients with AML and 11q23/MLL Rearrangement (MLL-R AML)
The authors analyzed the outcome of allogeneic hematopoietic stem-cell transplantation among adult patients reported to the ALWP between 2000 and 2010. They identified 159 patients with 11q23/MLL rearranged acute myeloid leukemia allografted in first complete remission or CR2, mostly corresponding to t(9;11), t(11;19), t(6;11), and t(10;11) translocations. [Leukemia] Abstract

Quantitative Characterization of T-Cell Repertoire in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Investigators comprehensively characterized the T-cell repertoire repertoire in patients who underwent matched donor or haplo-cord hematopoietic stem cell transplantation using next-generation sequencing approach. Their study defined the functional kinetics of each TCRA and TCRB clone, and changes in T-cell diversity and the extent of clonal expansion of certain T-cells. [Bone Marrow Transplant] Full Article

Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Overcomes Poor Prognosis of Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC)
Transplant outcomes of patients with AML-MRC have not been reported compared to patients with AML not otherwise specified (AML-NOS). Researchers analyzed transplant outcomes among 147 patients with AML-MRC or AML-NOS who underwent allo-HSCT in a single institution. [Leuk Lymphoma] Abstract

It all starts with the right cells! Order fresh and frozen primary cells now.
ERYTECH Announces Two Positive DSMB Reviews
ERYTECH Pharma announced positive safety reviews after the completion of the first cohort in the company’s US Phase I study with ERY-ASP in acute lymphoblastic leukemia, and following the treatment of the first three patients with ERY-ASP in combination with Folfox in its Phase II study in pancreatic cancer. [ERYTECH Pharma] Press Release

bluebird bio Reports New Beta-Thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 Study at EHA
bluebird bio, Inc. announced long-term follow up of two patients with beta-thalassemia major and early safety and efficacy data in the first patient with severe sickle cell disease treated with LentiGlobin BB305 product candidate in the HGB-205 study. [bluebird bio, Inc.] Press Release

From our sponsor: Learn about assays for cord blood. Download the free Technical Bulletin.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Metabolism in Cancer and Stromal Cells
September 8-10, 2015
Leuven, Belgium

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Position – Hematopoietic Stem Cell Transplantation (St. Jude Children’s Research Hospital)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Position – Hematopoietic Stem Cell and Hematologic Malignancy (University of Kentucky College of Medicine)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Harvard Medical School)

Postdoctoral Fellow – Cell Fate Decisions in Normal and Malignant Blood Stem Cells (University of Cambridge)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Postdoctoral Fellow – Immune Tolerance (Stanford University)

Postdoctoral Position – Epigenetic Regulation of Hematopoiesis and Leukemia (Karolinska Institute)

Postdoctoral Fellow – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us